Agenda & Speakers

19 Mar
Managing the Adverse Event of LEN+PEM Combination in 1st Line RCC


19 March 2024

8:00pm - 9:00pm (GMT+9)

Session 1 : Safety Management in 1st line treatment with Lenvatinib + Pembrolizumab
Dr. Viktor Grünwald
Dr. Viktor Grünwald
University Hospital Essen, Essen, Germany
Session 2: Case discussion in LEN+PEM safety management in Korea
Dr. Sun Young Rha
Dr. Sun Young Rha
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
Panel Discussion
Dr. Pongwut Danchaivijitr
Dr. Pongwut Danchaivijitr
Siriraj Hospital, Bangkok, Thailand
Dr. Sun Young Rha
Dr. Sun Young Rha
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
Dr. Viktor Grünwald
Dr. Viktor Grünwald
University Hospital Essen, Essen, Germany
Closing
Dr. Ravindran Kanesvaran
Dr. Ravindran Kanesvaran
National Cancer Center Singapore, Singapore
Please contact
[email protected]
if you have any enquiries